SURROZEN INC (SRZN) Stock Overview
USA - NASDAQ:SRZN - US86889P2083 - Common Stock
SRZN Key Statistics, Chart & Performance
The current stock price of SRZN is 11.55 USD. In the past month the price increased by 3.59%. In the past year, price increased by 30.21%.
SRZN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.85 | 390.07B | ||
| AMGN | AMGEN INC | 12.6 | 147.89B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 139.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.85 | 99.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.21B | ||
| ARGX | ARGENX SE - ADR | 79.22 | 44.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.79 | 39.49B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.59B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About SRZN
Company Profile
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 40 full-time employees. The company went IPO on 2020-11-23. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Company Info
SURROZEN INC
171 Oyster Point Blvd, Suite 400
South San Francisco CALIFORNIA US
CEO: Gad Soffer
Employees: 41
Phone: 16504752820
SURROZEN INC / SRZN FAQ
What is the stock price of SURROZEN INC today?
The current stock price of SRZN is 11.55 USD. The price decreased by -0.09% in the last trading session.
What is the ticker symbol for SURROZEN INC stock?
The exchange symbol of SURROZEN INC is SRZN and it is listed on the Nasdaq exchange.
On which exchange is SRZN stock listed?
SRZN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SURROZEN INC stock?
8 analysts have analysed SRZN and the average price target is 37.74 USD. This implies a price increase of 226.75% is expected in the next year compared to the current price of 11.55. Check the SURROZEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SURROZEN INC worth?
SURROZEN INC (SRZN) has a market capitalization of 98.98M USD. This makes SRZN a Micro Cap stock.
How many employees does SURROZEN INC have?
SURROZEN INC (SRZN) currently has 41 employees.
What are the support and resistance levels for SURROZEN INC (SRZN) stock?
SURROZEN INC (SRZN) has a support level at 11.54 and a resistance level at 12.21. Check the full technical report for a detailed analysis of SRZN support and resistance levels.
Is SURROZEN INC (SRZN) expected to grow?
The Revenue of SURROZEN INC (SRZN) is expected to decline by -40.33% in the next year. Check the estimates tab for more information on the SRZN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SURROZEN INC (SRZN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRZN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRZN, evaluating the profitability, health, valuation and growth aspects
- SURROZEN INC (SRZN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SURROZEN INC (SRZN) Sales and EPS estimates to see what analysts future expectations are.
- SURROZEN INC (SRZN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SURROZEN INC (SRZN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SURROZEN INC (SRZN) Stock Chart to make your own analysis
- SURROZEN INC (SRZN) Latest news and press-releases to stay up to date.
Does SURROZEN INC (SRZN) stock pay dividends?
SRZN does not pay a dividend.
What is the Price/Earnings (PE) ratio of SURROZEN INC (SRZN)?
SURROZEN INC (SRZN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.42).
What is the Short Interest ratio of SURROZEN INC (SRZN) stock?
The outstanding short interest for SURROZEN INC (SRZN) is 1.06% of its float. Check the ownership tab for more information on the SRZN short interest.
SRZN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRZN. When comparing the yearly performance of all stocks, SRZN is one of the better performing stocks in the market, outperforming 81.29% of all stocks.
SRZN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRZN. SRZN has a great financial health rating, but its profitability evaluates not so good.
SRZN Financial Highlights
Over the last trailing twelve months SRZN reported a non-GAAP Earnings per Share(EPS) of -14.42. The EPS increased by 5.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.25% | ||
| ROE | -35.43% | ||
| Debt/Equity | 0 |
SRZN Forecast & Estimates
8 analysts have analysed SRZN and the average price target is 37.74 USD. This implies a price increase of 226.75% is expected in the next year compared to the current price of 11.55.
For the next year, analysts expect an EPS growth of 59.05% and a revenue growth -40.33% for SRZN